To view Article Recommendations, you must have an active subscription.
If your access has expired, you can subscribe at $9.95 per month, the first month of your subscription will be free of charge.
If you think you should be able to access this content, please contact us.
New to F1000? See this week’s top article below for a free preview of a Recommendation.
This article makes significant advances in multiple areas: 1) the mammalian target of rapamycin (mTOR) signalling-related cap-dependent translation initiation mechanism, 2) the regulation of nutrient signalling-dependent 5' terminal oligopyrimidine (TOP) messanger (m)RNA...
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
8 Recommendations, most recent by| Confirmation | Good for Teaching | Interesting Hypothesis | New Finding
Past 7 Days
New Articles Recommended
Past 30 Days
178Articles Classified As Technical Advance22,520 total
256Articles Classified As Confirmation26,173 total
16Articles Classified As Refutation1,554 total
300Articles Classified As Good for Teaching3,778 total
285Articles Classified As Interesting Hypothesis27,063 total
100Articles Classified As Controversial9,944 total
3Articles Classified As Changes Clinical Practice1,471 total
918Articles Classified As New Finding103,486 total
62Articles Classified As Review / Commentary4,274 total
92Articles Classified As Novel Drug Target6,039 total
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.